Compare LPTH & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPTH | NBTX |
|---|---|---|
| Founded | 1985 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.8B |
| IPO Year | 2011 | 2018 |
| Metric | LPTH | NBTX |
|---|---|---|
| Price | $12.87 | $34.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $13.33 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 3.8M | 54.7K |
| Earning Date | 05-14-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,202,630.00 | N/A |
| Revenue This Year | $83.04 | $58.17 |
| Revenue Next Year | $24.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.26 | N/A |
| 52 Week Low | $2.75 | $4.57 |
| 52 Week High | $18.94 | $57.14 |
| Indicator | LPTH | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.96 | 41.03 |
| Support Level | $12.45 | $30.15 |
| Resistance Level | $13.28 | $34.66 |
| Average True Range (ATR) | 1.60 | 2.70 |
| MACD | -0.33 | -0.13 |
| Stochastic Oscillator | 2.68 | 32.07 |
LightPath Technologies Inc manufactures, distributes, and integrates proprietary optical components and assemblies. It develops optical solutions for traditional optics and communications markets. The company's products include precision molded optics and infrared products, serving markets such as distribution, laser, industrial, instrumentation, telecommunications, and defense. Its products are categorized as infrared components, visible components, assemblies and modules, and engineering services. G5 Infrared's revenue mainly comes from infrared components and assemblies.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.